While early clinical trials of the small molecule inhibitor of IDO1, epacadostat, in combination with the anti-PD-1 molecule pembrolizumab, showed promise, no benefit was found in a phase III trial in metastatic melanoma patients compared to pembrolizumab alone [25,26,27,28]. Here, IDO1 is linked to metastatic melanoma.